Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Neutrolin® will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session”In the company’s words, NCT02651428 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of this study is determine safety and effectiveness of Neutrolin, a catheter lock solution, for prevention of central venous catheter associated bloodstream infection in hemodialysis patients.”In the company’s words, NCT02651428 on ClinicalTrials.gov
Other drugs for Kidney Failure, Chronic
- Migalastat HClAmicus Therapeutics · Phase 3
- XyloCore StrenghtIperboreal Pharma Srl · Phase 3
- TegoprubartEledon Pharmaceuticals · Phase 3
- SymvessHumacyte, Inc. · Phase 3
- RoxadustatAstellas · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | Oct 2018 | Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026